Hemostatic wound dressing and fabric and methods of making and using same

• US 20040120993A1
• Filed: 12/20/2002
• Published: 06/24/2004
• Est. Priority Date: 12/20/2002
• Status: Abandoned Application

• Current Assignee: Ethicon Incorporated (Johnson & Johnson)
• Original Assignee: Ethicon Incorporated (Johnson & Johnson)
• Inventors: Zhang, Guanghui, Guo, Jian Xin, Looney, Dwayne Lee, Gorman, Anne Jessica, Pendharkar, Sanyog Manohar
• Application Number:
  US10/326,244
• Publication Number:
  US 20040120993A1
• Time in Patent Office: Days
• US Class Current: 424/445
• CPC Class Codes: A61L 15/28 Polysaccharides or their derivatives A61L15/225 takes precedence
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: C08L 1/02 Cellulose; Modified cellulose
• CPC Class Codes: C08L 1/04 Oxycellulose; Hydrocellulose , e.g. microcrystalline cellulose
• CPC Class Codes: C08L 5/00 Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
• CPC Class Codes: Y10T 442/2525 Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]

Abstract

The present invention is directed to hemostatic wound dressings containing a fabric made from biocompatible, aldehyde-modified polysaccharide fibers; and a porous, polymeric matrix made from a biocompatible, water-soluble or water-swellable polymer, dispersed at least partially through the fabric, to methods of making such wound dressings and to methods of providing hemostasis to a wound.

Claims

1. A hemostatic wound dressing, comprising:

a fabric, said fabric comprising a first wound-contacting surface and a second surface opposing said wound-contacting surface, said fabric comprising fibers and having flexibility, strength and porosity effective for use as a hemostat, said fibers comprising a biocompatible, aldehyde-modified polysaccharide; and

a porous, polymeric matrix applied to said wound-contacting surface and dispersed at least partially through said fabric, said porous polymeric matrix comprising a biocompatible, water-soluble or water-swellable polymer,

wherein said wound dressing is hemostatic.

2. The wound dressing of claim 1 wherein said aldehyde-modified polysaccharide is selected from the group consisting of cellulose, cellulose derivatives, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid and derivatives of the above.

3. The wound dressing of claim 2 wherein said aldehyde-modified polysaccharide comprises an amount of aldehyde effective to render the polysaccharide biodegradable.

4. The wound dressing of claim 3 wherein said aldehyde-modified polysaccharide is selected from the group consisting of starch, dextran, pectin, alginate, chitin, chitosan, glycogen, amylose, amylopectin, cellulose and cellulose derivatives thereof.

5. The wound dressing of claim 4 wherein said aldehyde-modified polysaccaride comprises aldehyde-modified regenerated polysaccharide.

6. The wound dressing of claim 5 wherein said aldehyde-modified polysaccharide comprises aldehyde-modified regenerated cellulose comprising repeating units of structure II,

7. The wound dressing of claim 1 wherein said aldehyde-modified polysaccharide is essentially free of carboxylic acid.

8. The wound dressing of claim 6 wherein said aldehyde-modified cellulose is essentially free of carboxylic acid.

9. The wound dressing of claim 1 further comprising a hemostatic agent.

10. The wound dressing of claim 9 wherein said hemostatic agent is synthetic, recombinant or naturally occurring.

11. The wound dressing of claim 10 wherein said hemostatic agent is selected from the group consisting prothrombin, thrombin, fibrinogen, fibrin, fibronectin, heparinase, Factor X/Xa, Factor VII/VIIa, Factor IX/IXa, Factor XI/XIa, Factor XII/XIIa, tissue factor, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin, gelatin, platelet surface glycoproteins, vasopressin, vasopressin analogs, epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet activating agents and synthetic peptides having hemostatic activity and derivatives of the above.

12. The wound dressing of claim 11 comprising from about 0.001 to about 50 percent by weight of said hemostatic agent.

13. The wound dressing of claim 8 wherein said water-soluble or water-swellable polymer is selected from the group consisting of non-acidic methyl cellulose, hydroxyalkyl cellulose, water-soluble chitosan, salts of carboxymethyl carboxyethyl cellulose, chitin, salts of hyaluronic acid, alginate, propylene glycol alginate, glycogen, dextran, carrageenans, chitosan, starch, amylose, poly-N-glucosamine and derivatives of the above and the aldehyde-modified derivatives thereof, said wound dressing comprising from about 0.001 to about 50 percent by weight of said hemostatic agent selected from the group consisting of thrombin, fibrin and fibrinogen.

14. The wound dressing of claim 13 comprising from about 0.001 to about 1 percent thrombin as the hemostatic agent.

15. The wound dressing of claim 13 comprising from about 0.1 to about 50 percent by weight of fibrinogen as the hemostatic agent.

16. The wound dressing of claim 13 comprising from about 0.1 to about 50 percent by weight of fibrin as the hemostatic agent.

17. The wound dressing of claim 9 comprising said hemostatic agent dispersed at least partially through said porous, polymeric matrix.

18. The wound dressing of claim 9 comprising said hemostatic agent dispersed substantially homogenously through said porous, polymeric matrix.

19. The wound dressing of claim 9 wherein said first wound-contacting surface of said fabric comprises said hemostatic agent.

20. The wound dressing of claim 9 comprising said hemostatic agent dispersed substantially homogenously through said fabric.

21. The wound dressing of claim 9 wherein said hemostatic agent is dispersed at least partially through said fabric.

22. The wound dressing of claim 1 wherein said water-soluble or water-swellable polymer is selected from the group consisting of polysaccharides, polyacrylic acids, polymethacrylic acids, polyamines, polyimines, polyamides, polyesters, polyethers, polynucleotides, polynucleic acids, polypeptides, proteins, poly (alkylene oxides), polythioesters, polythioethers, polyvinyls and polymers comprising lipids.

23. The wound dressing of claim 22 wherein said water-soluble or water-swellable polymer is a polysaccharide.

24. The wound dressing of claim 22 wherein said polysaccharide is selected from the group consisting of cellulose, cellulose derivatives, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid and derivatives of the above.

25. The wound dressing of claim 1 wherein said porous polymeric matrix comprises lyophilized sodium carboxymethyl cellulose.

26. The wound dressing of claim 25 wherein the weight ratio of said lyophilized sodium carboxymethyl cellulose to said fabric is from about 1:

99 to about 20;

80.

27. The wound dressing of claim 1 wherein said porous polymeric matrix is dispersed substantially homogeneously through said fabric.

28. The wound dressing of claim 1 wherein said porous polymeric matrix is dispersed through said fabric in a gradient, whereby the concentration of the water-soluble or water-swellable polymer adjacent said first wound-contacting surface is greater than the concentration of the water-soluble or water-swellable polymer adjacent said second opposing surface.

29. A fabric, comprising:

a first surface and a second surface opposing said first surface, said fabric comprising fibers comprising a biocompatible, aldehyde-modified polysaccharide.

30. The fabric of claim 29 wherein said fabric is hemostatic.

31. The fabric of claim 30 wherein said fibers comprise aldehyde-modified regenerated polysaccharide and said porous polymeric matrix comprises a lyophilized polysaccharide selected from the group consisting of cellulose, cellulose derivatives, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid and derivatives of the above.

32. The fabric of claim 29 wherein said fabric is essentially free of carboxylic acid.

33. The fabric of claim 29 further comprising a hemostatic agent.

34. The fabric of claim 30 further comprising a hemostatic agent.

35. A process for making a wound dressing:

comprising,

providing a solution having substantially dissolved therein a water-soluble or water-swellable biocompatible polymer,

providing a fabric having a top surface and a bottom surface opposing said top surface, said fabric comprising fibers and having flexibility, strength and porosity effective for use as a hemostat, said fibers comprising an aldehyde-modified polysaccharide,

contacting said solution with said fabric under conditions effective to distribute said solution through said fabric,

lyophilizing said fabric having said solution distributed there through, thereby providing a porous, polymeric matrix comprising said water-soluble or water-swellable polymer dispersed through said fabric.

36. The process of claim 35 wherein said fabric is knitted.

37. The process of claim 36 wherein said fibers comprise an aldehyde-modified regenerated cellulose.

38. The process of claim 37 wherein said porous polymeric matrix comprises a polymer selected from the group consisting of polysaccharides, polyacrylic acids, polymethacrylic acids, polyamines, polyimines, polyamides, polyesters, polyethers, polynucleotides, polynucleic acids, polypeptides, proteins, poly (alkylene oxides), polythioesters, polythioethers, polyvinyls, polymers comprising lipids and derivatives of the above.

39. The process of claim 38 wherein said porous polymeric matrix comprises a polysaccharide selected from the group consisting of cellulose, cellulose derivatives, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid and derivatives of the above.

40. The process of claim 39 wherein said porous polymeric matrix comprises sodium carboxymethyl cellulose, wherein the weight ratio of said sodium carboxymethyl cellulose to said fabric is from about 1:

99 to about 20;

80.

41. The process of claim 35 further comprising an effective amount of a hemostatic agent admixed with said solution.

42. A method of providing hemostasis to a wound, comprising:

applying to a wound a hemostatic wound dressing, comprising;

a fabric, said fabric comprising a first wound-contacting surface and a second surface opposing said wound-contacting surface, said fabric comprising fibers and having flexibility, strength and porosity effective for use as a hemostat, said fibers comprising a biocompatible, aldehyde-modified polysaccharide; and

a porous, polymeric matrix applied to said wound-contacting surface and dispersed at least partially through said fabric, said porous, polymeric matrix comprising a biocompatible, water-soluble or water-swellable polymer,

wherein said wound dressing is hemostatic.

43. The method of claim 42 wherein said aldehyde-modified polysaccharide is selected from the group consisting of cellulose, cellulose derivatives, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates, carboxymethyl dextran, carboxymethyl chitosan, heparin, heparin sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate, carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid, polyglucuronic acid, polyguluronic acid and derivatives of the above.

44. The method of claim 43 wherein said aldehyde-modified polysaccharide comprises an amount of aldehyde effective to render the polysaccharide biodegradable.

45. The method of claim 44 wherein said aldehyde-modified polysaccaride comprises aldehyde-modified regenerated polysaccharide.

46. The wound dressing of claim 45 wherein said aldehyde-modified polysaccharide comprises aldehyde-modified regenerated cellulose comprising repeating units of structure II,

47. The method of claim 42 wherein said aldehyde-modified polysaccharide is essentially free of carboxylic acid.

48. The method of claim 46 wherein said aldehyde-modified cellulose is essentially free of carboxylic acid.

49. The method of claim 42 wherein said wound dressing further comprises a hemostatic agent.

50. The method of claim 49 wherein said hemostatic agent is selected from the group consisting prothrombin, thrombin, fibrinogen, fibrin, fibronectin, heparinase, Factor X/Xa, Factor VII/VIIa, Factor IX/IXa, Factor XI/XIa, Factor XII/XIIa, tissue factor, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin, gelatin, platelet surface glycoproteins, vasopressin, vasopressin analogs, epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet activating agents and synthetic peptides having hemostatic activity and derivatives of the above.

51. The method of claim 42 wherein said porous, polymeric matrix comprises a polymer selected from the group consisting of polysaccharides, polyacrylic acids, polymethacrylic acids, polyamines, polyimines, polyamides, polyesters, polyethers, polynucleotides, polynucleic acids, polypeptides, proteins, poly (alkylene oxides), polythioesters, polythioethers, polyvinyls, polymers comprising lipids and derivatives of the above.